Updated results from the APPEAR-C3G trial – reported at the American Society of Nephrology (ASN) Kidney Week congress in San Diego over the weekend – showed that Fabhalta (iptacopan ...

Current treatment methods for C3 glomerulopathy (C3G) help support kidney function and suppress immune system activity. Emerging therapies interrupt the proteins responsible for disease activity.

[MUSIC PLAYING] FRITA MCRAE FISHER: C3 glomerulopathy, also known as C3G, is a kidney disease where there are certain deposits in the glomeruli. The glomeruli are the kidney's filtering units.

Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting a green light in ultra-rare kidney disease C3 glomerulopathy (C3G).

The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to reduce proteinuria. C3G is a progressive and ultra-rare kidney disease that is typically diagnosed ...

Carla Nester, MD, MSA, FASN, is coinvestigator for the ongoing APPEAR-C3G trial (NCT04817618), data from which were used to support the FDA’s recent approval of iptacopan (Fabhalta; Novartis ...

Highlights from CHMP’s February 24–27 meeting described C3G as “ultra-rare” and clarified that Fabhalta has already been granted orphan drug designation (1,2). Novartis announced CHMP’s decision in a ...

"C3G is a debilitating disease often affecting ... body aches with flu-like symptoms; or eyes sensitive to light. Health care providers will give their patients a Patient Safety Card about the ...

C3G is a progressive and ultra-rare kidney disease ... body aches with flu-like symptoms; or eyes sensitive to light. Health care providers will give their patients a Patient Safety Card about ...